Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew M Mason

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Journal of Medicinal Chemistry|January 5, 2002
Design and synthesis of pyrrolidine-5,5-trans-lactams (5-oxohexahydropyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease. 2. Potency and chiralityAlan D Borthwick, Andrew J Crame, Peter F Ertl, et al.
ACS Chemical Biology|November 30, 2017
Design and Application of a DNA-Encoded Macrocyclic Peptide LibraryZhengrong Zhu, Alex Shaginian, LaShadric C Grady, et al.
Pharmacology Research & Perspectives|December 14, 2019
MrgX2 is a promiscuous receptor for basic peptides causing mast cell pseudo-allergic and anaphylactoid reactionsJak Grimes, Sapna Desai, Neil W Charter, et al.
Journal of Medicinal Chemistry|January 14, 2012
Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potencyAlan D Borthwick, John Liddle, Dave E Davies, et al.
Bioorganic & Medicinal Chemistry Letters|May 16, 2006
Design and synthesis of orally active pyrrolidin-2-one-based factor Xa inhibitorsNigel S Watson, David Brown, Matthew Campbell, et al.
Bioorganic & Medicinal Chemistry Letters|December 7, 2007
Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with biaryl P4 motifsRobert J Young, Alan D Borthwick, David Brown, et al.
Bioorganic & Medicinal Chemistry Letters|November 23, 2007
The discovery of GSK221149A: a potent and selective oxytocin antagonistJohn Liddle, Michael J Allen, Alan D Borthwick, et al.
Bioorganic & Medicinal Chemistry Letters|September 20, 2006
Structure- and property-based design of factor Xa inhibitors: pyrrolidin-2-ones with acyclic alanyl amides as P4 motifsRobert J Young, Matthew Campbell, Alan D Borthwick, et al.
Bioorganic & Medicinal Chemistry Letters|December 7, 2007
Structure and property based design of factor Xa inhibitors: biaryl pyrrolidin-2-ones incorporating basic heterocyclic motifsRobert J Young, Alan D Borthwick, David Brown, et al.
Bioconjugate Chemistry|February 1, 2021
<i>In Vivo</i> Half-Life Extension of BMP1/TLL Metalloproteinase Inhibitors Using Small-Molecule Human Serum Albumin BindersJulien C Vantourout, Andrew M Mason, Josephine Yuen, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Journal of Medicinal Chemistry|January 5, 2002
Design and synthesis of pyrrolidine-5,5-trans-lactams (5-oxohexahydropyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease. 2. Potency and chiralityAlan D Borthwick, Andrew J Crame, Peter F Ertl, et al.
ACS Chemical Biology|November 30, 2017
Design and Application of a DNA-Encoded Macrocyclic Peptide LibraryZhengrong Zhu, Alex Shaginian, LaShadric C Grady, et al.
Pharmacology Research & Perspectives|December 14, 2019
MrgX2 is a promiscuous receptor for basic peptides causing mast cell pseudo-allergic and anaphylactoid reactionsJak Grimes, Sapna Desai, Neil W Charter, et al.
Journal of Medicinal Chemistry|January 14, 2012
Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potencyAlan D Borthwick, John Liddle, Dave E Davies, et al.
Bioorganic & Medicinal Chemistry Letters|May 16, 2006
Design and synthesis of orally active pyrrolidin-2-one-based factor Xa inhibitorsNigel S Watson, David Brown, Matthew Campbell, et al.
Bioorganic & Medicinal Chemistry Letters|December 7, 2007
Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with biaryl P4 motifsRobert J Young, Alan D Borthwick, David Brown, et al.
Bioorganic & Medicinal Chemistry Letters|November 23, 2007
The discovery of GSK221149A: a potent and selective oxytocin antagonistJohn Liddle, Michael J Allen, Alan D Borthwick, et al.
Bioorganic & Medicinal Chemistry Letters|September 20, 2006
Structure- and property-based design of factor Xa inhibitors: pyrrolidin-2-ones with acyclic alanyl amides as P4 motifsRobert J Young, Matthew Campbell, Alan D Borthwick, et al.
Bioorganic & Medicinal Chemistry Letters|December 7, 2007
Structure and property based design of factor Xa inhibitors: biaryl pyrrolidin-2-ones incorporating basic heterocyclic motifsRobert J Young, Alan D Borthwick, David Brown, et al.
Bioconjugate Chemistry|February 1, 2021
<i>In Vivo</i> Half-Life Extension of BMP1/TLL Metalloproteinase Inhibitors Using Small-Molecule Human Serum Albumin BindersJulien C Vantourout, Andrew M Mason, Josephine Yuen, et al.
Pageof 2